This study demonstrates that mRNA-encapsulated toxins reduce tumor growth in cancer models, suggesting a new immunotherapy strategy.
Abstract Treatment with mRNA-based therapeutics represents a potential strategy for improving outcomes of diverse diseases. Tumor-specific toxins might represent ideal candidates for mRNA-based cancer therapeutics. In this study, we investigated the antitumor potential of lipid nanoparticle (LNP)–encapsulated mRNA encoding the tumor-specific toxin protein neutrophil elastase (ELANE) or porcine pancreatic elastase (PPE). Treatment with either ELANE or PPE mRNA-LNP selectively killed various cancer cell types but not noncancer cells in vitro. Furthermore, ELANE and PPE mRNA-LNP administration significantly inhibited tumor growth in vivo and induced CD8⁺ T-cell infiltration, whereas no acute toxicity was observed in mice. Several additional elastases from different species were also effective against cancer cells. Altogether, these data support further development of tumor-specific toxin protein mRNA-LNP as a therapeutic strategy for cancer. Significance: Treatment with lipid nanoparticle-encapsulated mRNA encoding tumor-specific toxin proteins reduces tumor growth and activates antitumor immunity, providing an alternative approach for treating tumors that are resistant or unresponsive to immunotherapy.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: